19 November 2021 - If approved, bulevirtide will be the first treatment option for adult patients in the US with chronic hepatitis delta virus infection with compensated liver disease.

Gilead Sciences announced today that it has submitted a biologics license application to the US FDA for bulevirtide for injection (2 mg), a potential first in class antiviral medicine for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease; bulevirtide has been granted breakthrough therapy and orphan drug designations by the FDA.

Read Gilead press release